Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Survival Rate of Extrahepatic Cholangiocarcinoma Patients after Surgical Treatment in Thailand

  • Pattanathien, Pisit (Department of Epidemiology, Faculty of Public Health, Khon Kaen University) ;
  • Khuntikeo, Narong (Department of Surgery, Faculty of Public Health, Khon Kaen University) ;
  • Promthet, Supannee (Department of Epidemiology, Faculty of Public Health, Khon Kaen University) ;
  • Kamsa-ard, Supot (Cancer Unit, Faculty of Medicine, Khon Kaen University)
  • Published : 2013.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Intra- and extrahepatic cholangiocarcinoma (CCA) is the most common cancer in Thailand, especially in the northeast region. Most extrahepatic CCA patients consult a doctor at a late stage. Surgery is still the best treatment. Objectives: The aim of this study was to evaluate survival rates and factors affecting survival in extrahepatic CCA patients following surgery at Srinagarind Hospital, Khon Kaen University, Thailand. Materials and Methods: A retrospective cohort study was conducted with 58 patients who were diagnosed and treated by surgical resection by the same surgeon at Srinagarind Hospital between 2005 and 2009. The patients were followed up until death or the end of the study (31 December, 2011). Survival rates were calculated by the Kaplan-Meier method, and the Cox proportional hazard model was used to identify independent prognostic factors. Results: The total follow-up time was 1,215 person-months, and the mortality rate was 50 per 100 person-years. The cumulative 1-, 3-, and 5-year survival rates were 62.1%, 21.7% and 10.8%, respectively. The median survival time after resection was 15 months. After adjusting for age, gender, lymph node metastasis and histological type, resection margin remained as a statistically significant prognostic factor for survival following surgery. A positive resection margin was associated with a 2.3-fold higher mortality rate than a negative margin. Conclusions: Resection margins are important prognostic factors affecting survival of extrahepatic CCA patients after surgery. A negative resection margin can reduce the mortality rate by 56%.

Keywords

References

  1. American Cancer Society. Cancer facts and figures (2009). Atlanta: American Cancer Society.
  2. American Joint Committee on Cancer (2002). AJCC Cancer Staging Manual: In Extrahepatic bile ducts. 6th ed. New York: Springer.
  3. Anderson BB, Ukah F, Tette A, et al (1992). Primary tumors of the liver. J National Med Assoc, 84, 129-35.
  4. Bhudhisawasdi V (1997). Place of surgery in opisthorchiasis associated cholangiocarcinoma. Southeast Asian J Trop Med Public Hlth, 28, 85-90.
  5. Cancer Unit, Srinagarind Hospital (2010). Hospital-based tumor registry 2009: statistical report. Khon Kaen: Faculty of Medicine, Khon Kaen University.
  6. Fuller CD, Wang SJ, Choi M, et al (2009). Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population based analysis. PMC, 115, 5175-83.
  7. Jarnagin WR, Bowne W, Klimstra DS, et al (2005). Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg, 241, 703-14. https://doi.org/10.1097/01.sla.0000160817.94472.fd
  8. Khuhaprema T, Srivatranakul P, Attasara P, et al editors (2010). Cancer in Thailand: Vol. V, 2001-2003. Bangkok: Bangkok Medical Publisher.
  9. Khuntikeo N, Phugkhem A, Bhudhisawasdi V, et al (2008). Major hepatic resection for hilar cholangiocarcinoma without preoperative biliary drainage. Asian Pac J Cancer Prev, 9, 83-5.
  10. Kosuge T, Yamamoto J, Shimada K, et al (1999). Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg, 230, 663-71. https://doi.org/10.1097/00000658-199911000-00008
  11. Li H, Qin Y, Cui Y, et al (2011). Analysis of the surgical outcome and prognostic factors for hilar cholangiocarcinoma: A Chinese experience. Dig Surg, 28, 226-31. https://doi.org/10.1159/000327361
  12. Murakami Y, Uemura K, Sudo T, et al (2011). Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol, 18, 651-8. https://doi.org/10.1245/s10434-010-1325-4
  13. Neuhaus P, Jonas S, Bechstein WO, et al (1999). Extended resection for hilar cholangiocarcinoma. Ann Surg, 230, 808-19. https://doi.org/10.1097/00000658-199912000-00010
  14. Ohtsuka M, Ito H, Kimura F, et al (2003). Extended hepatic resection and outcomes in intrahepatic cholangiocarcinoma. J Hepato-Biliary-Pancreatic Surg, 10, 259-64. https://doi.org/10.1007/s00534-002-0724-8
  15. Poomphakwaen K, Promthet S, Kamsa-ard S, et al (2009). Risk factors for cholangiocarcinoma in Khon Kaen, Thailand : a nested case-control study. Asian Pac J Cancer Prev, 10, 251-8.
  16. Shi QF, Liang TB, Qin YS, et al (2007). Evaluation of surgical approach for extrahepatic cholangiocarcinoma. Hepatobiliary Pancreat Dis Int, 6, 622-6.
  17. Sriamporn S, Black R, Sankaranarayanan R, et al (1995). Cancer survival in Khon Kaen Province, Thailand. Int J Cancer, 61, 296-300. https://doi.org/10.1002/ijc.2910610303
  18. Sripa B, Brindley PJ, Mulvenna J, et al (2012). The tumorigenic liver fluke Opisthorchis viverrrini ? multiple pathways to cancer. Trends Parasitol, 28, 395-407. https://doi.org/10.1016/j.pt.2012.07.006
  19. Sriplung H, Sontipong S, Martin N, et al (2005). Cancer incidence in Thailand, 1995-1997. Asian Pac J Cancer Prev, 6, 276-81.
  20. Sriplung H, Wiangnon S, Sontipong S, et al (2006). Cancer incidence trends in Thailand, 1989-2000. Asian Pac J Cancer Prev, 7, 239-44.
  21. StataCorp LP (2007). Stata Release 10: User's guide. College Station TX: Stata Press.
  22. Unno M, Katayose Y, Rikiyama T, et al (2010). Major hepatectomy for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci, 17, 463-9. https://doi.org/10.1007/s00534-009-0206-3
  23. Uttaravichien T, Bhudhisawasdi V, Pairojkul C, et al (1999). Intrahepatic cholangiocarcinoma in Thailand. J Hepato- Biliary-Pancreatic Surg, 6, 128-35. https://doi.org/10.1007/s005340050095
  24. Vatanasapt V, Martin N, Sriplung H, et al (1995). Cancer incidence in Thailand 1988-1991. Cancer Epidemiol, Biomarkers and Prev, 4, 475-83.
  25. Witzigmann H, Berr F, Ringel U, et al (2006). Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma. Ann Surg, 244, 230-9. https://doi.org/10.1097/01.sla.0000217639.10331.47
  26. Yubin L, Chihua F, Zhixiang J, et al (2008). Surgical management and prognostic factors of hilar cholangiocarcinoma: Experience with 115 cases in China. Ann Surg Oncol, 15, 2113-9. https://doi.org/10.1245/s10434-008-9932-z

Cited by

  1. Factors Affecting Survival Time of Cholangiocarcinoma Patients: A Prospective Study in Northeast Thailand vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.1623
  2. Survival Analysis of Biliary Tract Cancer Cases in Turkey vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6025
  3. Surgical management of perihilar cholangiocarcinoma: a Khon Kaen experience vol.21, pp.8, 2014, https://doi.org/10.1002/jhbp.74
  4. Plasma Autoantibodies against Heat Shock Protein 70, Enolase 1 and Ribonuclease/Angiogenin Inhibitor 1 as Potential Biomarkers for Cholangiocarcinoma vol.9, pp.7, 2014, https://doi.org/10.1371/journal.pone.0103259
  5. Expression of Lamininγ2 in Extrahepatic Cholangiocarcinoma Tissues and its Influence on Tumor Invasion and Metastasis vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.2099
  6. Clinical analysis of cholangiocarcinoma patients receiving adjuvant radiotherapy vol.5, pp.6, 2016, https://doi.org/10.3892/mco.2016.1072
  7. Survival outcomes and progonostic factors of extrahepatic cholangiocarcinoma patients following surgical resection: Adjuvant therapy is a favorable prognostic factor vol.2, pp.6, 2014, https://doi.org/10.3892/mco.2014.377
  8. A Comprehensive Public Health Conceptual Framework and Strategy to Effectively Combat Cholangiocarcinoma in Thailand vol.10, pp.1, 2016, https://doi.org/10.1371/journal.pntd.0004293
  9. A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma vol.13, pp.5, 2017, https://doi.org/10.3892/ol.2017.5847
  10. Cohort profile: cholangiocarcinoma screening and care program (CASCAP) vol.15, pp.1, 2015, https://doi.org/10.1186/s12885-015-1475-7